Delivery Order SPE2DR25D9313-SPE2DR26FSFJ2

The Defense Logistics Agency awarded a $37,989.81 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of JAKAFI 10 mg tablets (60-count units). The award, issued on January 30, 2026, with an ultimate completion date of February 2, 2026, was made without set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which carries a $499.9 billion ceiling value and extends through December 31, 2036.

DMS Pharmaceutical Group Inc. serves as a critical supplier within the Department of Defense's pharmaceutical supply chain, leveraging its established performance across the PPV-G GEN V program to deliver a comprehensive range of branded and generic prescription medications, biologics, vaccines, and medical consumables to military healthcare facilities worldwide. The contractor's substantial federal contracting activity and demonstrated capability to fulfill diverse pharmaceutical requirements position it as a reliable vendor for supporting recurring medical supply needs across the military healthcare system. The company maintains no identified subcontractor relationships in its award documentation.